Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan | Zendy

Toyoaki Sawano | Zendy; Akihiko Ozaki | Zendy; Hiroaki Saito | Zendy; Yuki Shimada | Zendy; Tetsuya Tanimoto | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan

Author(s) -

Toyoaki Sawano,

Akihiko Ozaki,

Hiroaki Saito,

Yuki Shimada,

Tetsuya Tanimoto

Publication year - 2019

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2019.3817

Subject(s) - payment , valsartan , business , transparency (behavior) , medicine , randomized controlled trial , finance , actuarial science , law , political science , blood pressure

Key Points Question What is the extent of payments from pharmaceutical companies to authors who wrote the 5 retracted articles on the valsartan clinical trials after the revelation of the scandal in 2013? Findings A retrospective cross-sectional analysis using pharmaceutical companies’ data in 2016 showed that 30 of 50 authors (60%) associated with the 5 articles received payments from pharmaceutical companies, with 10% of authors receiving payment in the Japanese yen of more than ¥5 million. The total payment to the corresponding author of these 5 articles accounted for 43.2% of the total payments. Meaning Study finding suggest that clinical trial practitioners received large payments from the pharmaceutical industry even after the unprecedented scandal.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research